A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Molibresib (Primary) ; Abiraterone; Enzalutamide; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors GlaxoSmithKline

Most Recent Events

19 Jul 2019 Status changed from active, no longer recruiting to recruiting.
19 Jul 2019 Planned End Date changed from 29 Jul 2019 to 28 Feb 2022.
19 Jul 2019 Planned primary completion date changed from 28 Sep 2018 to 26 Feb 2021.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight